Company
LON:INS
Instem PLC is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for study management, regulatory submissions, clinical trial acceleration, and informatics-based insight generation. The company's solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster.
109 stories · page 4 of 6
"I am particularly pleased to confirm funds released through the hedging facility will not carry any geographical restrictions. This means we will be able to deploy capital across our entire portfolio," said CEO, Matt Lofgran
"Following a period of planned strategic progress, Instem is now undoubtedly better positioned for profitable growth than ever before”
If the 7,300 level were a fence, Footsie would have spent the whole day sitting on it
Archive
Carnival and Thomas Cook issue trading updates tomorrow with the devastating Caribbean hurricanes likely to be key features of both
Archive
A glance at some of the stories on the Proactive newswire today
The accounting treatment decided upon for the contract jibes with the line taken by investment analysts in their current year forecasts
Archive
A glance at some of the stories on the Proactive newswire today
Recurring revenue and SaaS [pay-as–you-go] software revenue grew 21% and 38%
Archive
Thomas Cook posts a trading update tomorrow as the European travel industry continues to face challenging trading conditions
Archive
Hurricane Energy kicks off the Halifax well; MySQUAR user base smashes through the 7.5mln mark; Orosur Mining sees big uptick in profits and cash inflow; plus more…
The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.
MaryBeth Thompson has more than 18 years of experience in the life sciences industry
Archive
A glance at today's headlines on the Proactive newswire ...
A final £0.7mln had been due subject to Instem Clinical – formerly Logos Holdings – meeting certain performance-related goals, which have been missed
There are a “range of possible outcomes” for the year, Instem said. The outlook for 2017 remains “encouraging”, it added.
An abridged round-up of today's stories on the Proactive newswire
Logging the data generated in clinical trials for new drugs is Instem’s core business
Instem has positioned itself to address the requirements of the new Standard for the Exchange of Non-clinical Data or SEND.
